Trade Margin Caps
-
{
- All
- News
-
Supreme Court Flags Massive Gap Between Medicine MRP And Retailer Cost, Asks Government, "Allowing This To Happen?"
The Court was hearing a public interest litigation (PIL) filed by advocate Kishan Chand Jain seeking mandatory generic drug prescriptions, strict initial price controls on non-scheduled medicines, and statutory margin caps on medical devices under the Drug Price Control Order (DPCO).
-
Centre Expects Anti-Cancer Drug Prices To Fall 20-70 Per Cent Under Proposed Trade Margin Cap
The Centre has told the Supreme Court that capping trade margins on anti-cancer medicines at 30 per cent of their maximum retail price (MRP) is expected to save patients around Rs 2,500 crore annually, with the proposed measure likely to reduce the MRP of such drugs by 20 to 70 per cent.
-
Government Caps Cancer Drug Trade Margins At 30%, Supreme Court Asks: Why Regulate Only Cancer Medicines?
While the proposed cap could reduce cancer treatment costs, the Supreme Court wants the government to explain why similar restrictions cannot be considered for other medicines and medical devices.
-
Supreme Court Flags Massive Gap Between Medicine MRP And Retailer Cost, Asks Government, "Allowing This To Happen?"
The Court was hearing a public interest litigation (PIL) filed by advocate Kishan Chand Jain seeking mandatory generic drug prescriptions, strict initial price controls on non-scheduled medicines, and statutory margin caps on medical devices under the Drug Price Control Order (DPCO).
-
Centre Expects Anti-Cancer Drug Prices To Fall 20-70 Per Cent Under Proposed Trade Margin Cap
The Centre has told the Supreme Court that capping trade margins on anti-cancer medicines at 30 per cent of their maximum retail price (MRP) is expected to save patients around Rs 2,500 crore annually, with the proposed measure likely to reduce the MRP of such drugs by 20 to 70 per cent.
-
Government Caps Cancer Drug Trade Margins At 30%, Supreme Court Asks: Why Regulate Only Cancer Medicines?
While the proposed cap could reduce cancer treatment costs, the Supreme Court wants the government to explain why similar restrictions cannot be considered for other medicines and medical devices.
